San Diego, California, United States · On-site
The New Product Planning Manager is a high impact role that will support the strategy, planning and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position will report to the Director…
Skills: Market analysis, Primary research, Secondary research, Competitive intelligence, Target product profiles
San Mateo, California, United States · On-site
About the Team At Genesis Molecular AI, we're a tight-knit team of deep learning researchers, computational scientists, and drug discovery pioneers united by a single mission: to develop the next generation of AI-driven …
Skills: Geometric Deep Learning, Molecular Dynamics, Equivariant Neural Networks, Diffusion Models, Free Energy Calculations
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The manager will support the strategy, planning, and execution of commercial assessments for AI-enabled pipeline programs. They will conduct market analysis, monitor competitors, and contribute commercial input to clinical development plans and target product profiles.
Candidates should have a life sciences background with a bachelor's or master's degree in biology or a related field. Experience in consulting, investment banking, or pharmaceutical new product planning is preferred, along with strong analytical and modeling skills.
The New Product Planning Manager is a high impact role that will support the strategy, planning and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position will report to the Director of New Product Planning.
This role will be hybrid 2-3 days a week based at Genesis’s San Diego office.
Market analysis: Analyze disease areas, treatment paradigms, and unmet needs to help shape the positioning of new potential drugs
Primary and secondary research: Support KOL interviews, along with secondary research such as epidemiology and published literature, to build and validate commercial assumptions
Competitive monitoring: Track competitor pipelines, clinical readouts, approvals, and deals, including monitoring conference abstracts and presentations for early signals, and translate the implications into updated assumptions for the team
Development strategy: Contribute commercial input into Target Product Profiles (TPPs) and clinical development plans (endpoints, comparators, patient populations, and indication sequencing)
Cross-functional collaboration: Work with discovery, preclinical development, business development, and finance to keep programs aligned with commercial objectives
Life sciences background, ideally a BS or MS degree in biology or a related field
1-2 years at a top-tier consulting firm, investment bank, or equity research group preferred
Experience in New Product Planning, marketing, portfolio strategy, competitive intelligence, or a related analytical role at a pharmaceutical or biotech company also considered
Experience in oncology or immunology is a plus
Some exposure to commercial assessments based on primary and secondary research, ideally for preclinical and early clinical assets
Strong Excel modeling and PowerPoint skills
Excellent communication, listening, and presentation skills
Ability to travel domestically and internationally, if required, approximately 10% of the time
Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. Genesis has also signed category-leading AI-pharma deals, the most recent of which was a significant expansion with Incyte (see coverage in Forbes and GEN) with a total potential deal value of several billion dollars.
Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.
Offices: Chapin Ave, Burlingame, California 94010, US · Sorrento Valley Blvd, Suite 8, San Diego, California 92121, US · New York, New York , US
Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.
Offices: Chapin Ave, Burlingame, California 94010, US · Sorrento Valley Blvd, Suite 8, San Diego, California 92121, US · New York, New York , US
